Advertisement

Managing the Prodrome of Schizophrenia

  • W. Wolfgang FleischhackerEmail author
  • Alexander M. Simma
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 212)

Abstract

It is a well-known fact that managing schizophrenia patients as early as possible has a positive impact on the psychopathological and psychosocial outcomes of the disorder. Identifying people at risk for this serious disorder before its outbreak has become a major research aim in the past decade. Consequently, the intuitive notion that intervening at this early stage, before a diagnosis of schizophrenia is established, could be a preventive measure has been scientifically studied. In this context, a number of interventions, both pharmacological and psychosocial, have been evaluated in prospective controlled clinical trials. Amisulpride, olanzapine, risperidone, omega-3 fatty acids, and antidepressants have been compared to placebo or other control interventions and have been found somewhat helpful. With the exception of omega-3 fatty acids, however, the original positive findings were not maintained in follow-up studies. In addition, the rates of conversion to psychosis, although generally lower in the experimental treatment groups, were also reasonably low in the control groups. Similar findings have been established in psychotherapy trials.

All evidence taken together makes it difficult to justify specific interventions at the prodromal stage of schizophrenia from the perspective of preventing or delaying the onset of the disorder. On the other hand, as many of the affected individuals suffer considerably, symptomatic treatment certainly is called for even though the evidence whether it should be pharmacological or psychosocial is not yet available.

Keywords

Schizophrenia Prodrome High risk Prevention Antipsychotics Antidepressants Omega-3 fatty acids Psychotherapy CBT Early intervention Prophylaxis 

References

  1. Addington J, Epstein I, Liu L, French P, Boydell K, Zipursky RB (2011a) A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 125(1):54–61PubMedCrossRefGoogle Scholar
  2. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R (2011b) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168(8):800–805PubMedCrossRefGoogle Scholar
  3. Amminger G, Schäfer M, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67(2):146–154PubMedCrossRefGoogle Scholar
  4. Bechdolf A, Wagner M, Veith V, Ruhrmann S, Pukrop R, Brockhaus-Dumke A, Berning J, Stamm E, Janssen B, Decker P, Bottlender R, Möller HJ, Gaebel W, Maier W, Klosterkötter J (2007) Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry 1(1):71–78PubMedCrossRefGoogle Scholar
  5. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Möller H-J, Gaebel W, Häfner H, Maier W, Klosterkötter J (2012) Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 200(1):22–29PubMedCrossRefGoogle Scholar
  6. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, McGorry PD (2008) Ethyl-eicosapentaenoic acid in first-episode psychosis: a 1H-MRS study. Neuropsychopharmacology 33(10):2467–2473PubMedCrossRefGoogle Scholar
  7. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry 68(4):546–557PubMedCrossRefGoogle Scholar
  8. Dell’osso B, Altamura AC (2010) Duration of untreated psychosis and duration of untreated illness: new vistas. CNS Spectr 15(4):238–246PubMedGoogle Scholar
  9. Fenton WS, Hibbeln J, Knable M (2000) Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47(1):8–21PubMedCrossRefGoogle Scholar
  10. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012) Predecting psychosis: meta-analysis of transition outcomes in individuals in high clinical risk. Arch Gen Psychiatry 69(3):220–229PubMedCrossRefGoogle Scholar
  11. Gross G, Huber G (1985) Psychopathology of basic stages of schizophrenia in view of formal thought disturbances. Psychopathology 18(2–3):115–125PubMedCrossRefGoogle Scholar
  12. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P (2011) Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168(12):1311–1317PubMedGoogle Scholar
  13. Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Möller HJ, Riecher-Rössler A (2011) Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull, 10 (Schizophr Bull first published online 2011 November 10), doi: 10.1093/schbul/sbr145Google Scholar
  14. Malla AK, Bodnar M, Joober R, Lepage M (2011) Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr Res 125(1):13–20PubMedCrossRefGoogle Scholar
  15. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163(5):790–799PubMedCrossRefGoogle Scholar
  16. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59(10):921–928PubMedCrossRefGoogle Scholar
  17. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parkers S, Bentall RP (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291–297PubMedCrossRefGoogle Scholar
  18. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, Lewis SW (2007) Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 33(3):682–687PubMedCrossRefGoogle Scholar
  19. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TØ, Krarup G, Jørgensen P, Jeppesen P (2006) Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 83(1):29–40PubMedCrossRefGoogle Scholar
  20. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, Francey SM, Yung AR (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96(1–3):25–33PubMedCrossRefGoogle Scholar
  21. Piomelli D, Pilon C, Giros B, Sokoloff P, Martres MP, Schwartz JC (1991) Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353(6340):164–167PubMedCrossRefGoogle Scholar
  22. Ruhrmann S, Schultze-Lutter F, Klosterkötter J (2003) Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36(Suppl 3):S162–S167PubMedGoogle Scholar
  23. Ruhrmann S, Bechdolf A, Kühn K-U, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Häfner H, Gaebel W, Möller HJ, Maier W, Klosterkötter J; LIPS study group (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry 191(51):88–95CrossRefGoogle Scholar
  24. World Health Organisation (2001) World Health Report 2001—Mental health: new understanding, new hope. GenevaGoogle Scholar
  25. Yung AR, Phillips LJ, Yuen HP, McGorry PD (2004) Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 67:131–142PubMedCrossRefGoogle Scholar
  26. Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons M, Ross ML, Kelly D, Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, McGorry PD (2011) Randomized controlled trial of interventions for young people at ultra high risk for psychosis. J Clin Psychiatry 72(4):430–440PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • W. Wolfgang Fleischhacker
    • 1
    Email author
  • Alexander M. Simma
    • 1
  1. 1.Department of Psychiatry and PsychotherapyMedical University InnsbruckInnsbruckAustria

Personalised recommendations